HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+14.45%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$3.02B
AUM Growth
-$28M
(-0.92%)
Cap. Flow
-$333M
Cap. Flow
% of AUM
-11.05%
Top 10 Holdings %
Top 10 Hldgs %
49.86%
Holding
57
New
11
Increased
11
Reduced
17
Closed
14
Top Buys
| 1 |
Stryker
SYK
|
$137M |
| 2 |
Cigna
CI
|
$125M |
| 3 |
AGN
Allergan plc
AGN
|
$105M |
| 4 |
CVS Health
CVS
|
$101M |
| 5 |
Medtronic
MDT
|
$92.7M |
Top Sells
| 1 |
Baxter International
BAX
|
$133M |
| 2 |
Merck
MRK
|
$126M |
| 3 |
Thermo Fisher Scientific
TMO
|
$114M |
| 4 |
Elevance Health
ELV
|
$102M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$90.9M |
Sector Composition
| 1 | Healthcare | 88.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neurocrine Biosciences
NBIX
$13.5B
| $50.5M | 1.67% |
410,356
-383,599
| -48% | -$47.2M |
|
|
CERN
27
DELISTED
Cerner Corp
CERN
| $47M | 1.56% |
729,050
-32,890
| -4% | -$2.12M |
|
28
Vertex Pharmaceuticals
VRTX
$102B
| $39M | 1.29% |
202,180
-143,370
| -41% | -$27.6M |
|
29
Dynavax Technologies
DVAX
$1.19B
| $38.7M | 1.28% |
3,121,469
+590,362
| +23% | +$7.32M |
|
30
Haemonetics
HAE
$2.57B
| $34.3M | 1.14% |
+299,239
| New | +$34.3M |
|
31
Danaher
DHR
$143B
| $30M | 1% |
311,554
-261,842
| -46% | -$25.2M |
|
|
CVRS
32
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $28.4M | 0.94% |
19,981,655
| – | – |
|
|
VRAY
33
DELISTED
ViewRay, Inc.
VRAY
| $23.6M | 0.78% |
+2,522,380
| New | +$23.6M |
|
34
Amneal Pharmaceuticals
AMRX
$3B
| $23M | 0.76% |
+1,036,110
| New | +$23M |
|
|
MDCO
35
DELISTED
Medicines Co
MDCO
| $20.4M | 0.68% |
682,200
-321,748
| -32% | -$9.62M |
|
|
PTE
36
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $13.8M | 0.46% |
28,852
+19,069
| +195% | +$9.11M |
|
37
Gilead Sciences
GILD
$140B
| $10.3M | 0.34% |
+132,870
| New | +$10.3M |
|
38
Bio-Rad Laboratories Class A
BIO
$7.8B
| $5.08M | 0.17% |
+16,240
| New | +$5.08M |
|
39
Biogen
BIIB
$20.5B
| $4.1M | 0.14% |
+11,610
| New | +$4.1M |
|
40
ICU Medical
ICUI
$3.06B
| $2.94M | 0.1% |
+10,380
| New | +$2.94M |
|
|
ZSAN
41
DELISTED
Zosano Pharma Corporation
ZSAN
| $2.27M | 0.08% |
15,869
| – | – |
|
42
Amgen
AMGN
$153B
| – | – |
-51,510
| Closed | -$9.51M |
|
|
43
Baxter International
BAX
$12.1B
| – | – |
-1,800,000
| Closed | -$133M |
|
44
Bristol-Myers Squibb
BMY
$96.7B
| – | – |
-488,750
| Closed | -$27M |
|
45
Centene
CNC
$14.8B
| – | – |
-586,360
| Closed | -$36.1M |
|
46
Exact Sciences
EXAS
$9.33B
| – | – |
-572,240
| Closed | -$34.2M |
|
47
Hologic
HOLX
$14.7B
| – | – |
-345,900
| Closed | -$13.8M |
|
48
Masimo
MASI
$7.43B
| – | – |
-747,040
| Closed | -$72.9M |
|
49
Myriad Genetics
MYGN
$633M
| – | – |
-58,335
| Closed | -$2.18M |
|
50
Qiagen
QGEN
$10.1B
| – | – |
-1,360,735
| Closed | -$52.2M |
|